The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2023 | Approaching patients with FLT3-mutated AML who are ineligible for high-intensity chemotherapy
In this video, Andrius Žučenka, MD, Vilnius University Hospital Santaros Klinikos, Vilnius, Lithuania, discusses the current standard of care (SOC) for patients with FLT3-mutated acute myeloid leukemia (AML) who are ineligible for high-intensity chemotherapy and FLT3 inhibitors, highlighting different approaches for patients with FLT3-ITD and FLT3-TKD mutations. Dr Žučenka then goes on to discuss the promise of triplet regimens in this space. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: Abbvie, Astellas, Pfizer, Novartis, Janssen
Honoraria: Abbvie, Astellas, Novartis, Janssen
Travel Expenses: Abbvie, Novartis, Janssen, Takeda
